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The immunosuppressive agent FK-506 has received much attention due to its efficacy and potency in the areas of transplant rejection and 
autoimmune disease. Calcineurin, a Ca*‘-calmodulin activated phosphatase, was recently implicated in the immunosuppressive mechanism of 
FK-506. In our ongoing search for superior immunosuppressive agents, we have synthesized several analogues of FK-506 and tested their 
mechanistic and immunosuppressive actions. It was found that C-18 hydroxyl analogues of ascomycin, an analogue of FK-506 also called 
FR900520, bound tightly to immunophilin FKBP-12, but do not show any immunosuppressive activity in vitro or in vivo despite good bioavail- 
ability. Further, they reverse the inhibition of calcineurin caused by FK-506/FKBP-12 complex. 
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1. INTRODUCTION 
The report by Fujisawa researchers in 1987 that the 
macrolactam antifungal FK-506, 1, isolated from the 
fermentation broth of Streptomyces tsukubaensis, pos- 
sessed powerful immunosuppressive activity set off a 
detailed investigation for its mechanism of action [l]. 
FK-506, which is 10-100 times more potent than the 
known immunosuppressive agent, cyclosporin A (CsA) 
4, has inhibitory effects on the production of various 
cytokines (IL-2, IL-3, IFN-7) and on the expression of 
alloantigen-induced human lymphocyte IL-2 receptors 
(IL-2R, Tat antigen) and transferrin receptors [2,3]. Al- 
though FK-506 is structurally distinct from CsA, it pos- 
sessed similar biological and immunological properties. 
Efforts to ascertain the mechanism of action of FK- 
506 have narrowed the site of action to the calcium- 
dependent signal transduction pathway in the T-cell ac- 
tivation cascade [4]. This ultimately led to the character- 
ization of FK-506 binding proteins (FKBP) that are 
present in relatively high concentrations (5 nanomolar) 
in cells of a variety of organisms [5] and that possess 
cis-tram peptidyl-prolyl isomerase activity [6-l 11. Re- 
cent efforts by Schreiber and co-workers have led to the 
identification of calcineurin which is believed to play a 
critical role in the immunosuppressive mechanism of 
FK-506 [12-141. FKBP is an essential component for 
inhibition of T-cell activation by FK-506, and the 
FKBP-FK506 complex, but not FK-506 alone, binds to 
and inhibits calcineurin commonly found in cells 
[12,13]. 
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Another structurally related immunosuppressant, ra- 
pamycin 3 that forms a complex with FKBP but inhibits 
T-cell activation through a different mechanism, has 
recently been highlighted due to its impressive and dis- 
tinct biological activity [15-l 71. These two structurally 
similar, but mechanistically distant molecules (1 and 3, 
along with a synthetic FK-506 analogue (506BD) [18] 
are thought to possess two domains, i.e. a binding do- 
main (the ‘left side’ of the molecule as drawn in l-3 a - -3 
domain that binds to FKBP) and an effector domain 
(the ‘right side’ of the molecules as drawn in 1-2, a 
domain thought to be necessary for calcineurin interac- 
tion [19]. 
We have initiated synthetic efforts to elucidate the 
structural features in ascomycin 2 [20,21] a homologue 
of FK-506 also known as FR-900520, that determine its 
biological activity. As observed by others [18,22] modi- 
fication of the effector domain can cause notable 
changes in biological and pharmacological activity. We 
report here the synthesis and biological characterization 
of a series of synthetic analogues. Ascomycin 2, which 
differs from FK-506 by only one carbon, possesses the 
same potent biological effects as FK-506, and has been 
used exclusively herein for the chemical modifications. 
1. EXPERIMENTAL 
2.1. Medium and reagents 
Ascomycin 2 was produced by fermentation with a method similar 
to that described in the literature [23]. Unless otherwise indicated, 
reagents were purchased from Sigma Chemical Co. (St. Louis, MO). 
Penicillin-streptomycin was purchased from Gibco Laboratories 
(Grand Island, NY). Complete RPM1 1640 contained 10% heat-inac- 
tivated fetal bovine serum, 50 PM 2-mercaptoethanol, 2 mM t_-glu- 
tamine, 100 U/ml penicillin, and 100 &ml streptomycin. FK-506 
binding protein (FKBP) and the fusion protein composed of FKBP 
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and CMP-KDO synthetase (FKBP/CKS) were prepared at Abbott 
Laboratories (Abbott Park, IL) as previously described [24]. 
2.2. Peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were isolated by 
Ficoll-Hypaque density gradient centrifugation of heparinized blood 
from healthy donors. Stimulator PBMC were treated with 25 @ml 
of mttomycin C for 30 min and washed before being used. 
2.3. Human mixed leukocyte response 
One way allogeneic mixed leukocyte response assays were per- 
formed as described by Kino et al. [26] with slight modification. 
Briefly, 1 x lo5 responder PBMC were mixed with 4 x 10’ stimulator 
PBMC, composed of 1 x lo5 PBMC from each of four different do- 
nors, in 0.2 ml of complete RPM1 1640 and cultured for 96 h at 37°C. 
During the final 6 h, the cells were labeled with 0.5 @i per well of 
tritiated thymidine [-‘H]TdR; DuPont NEN Research Products, Bos- 
ton, MA). The cells were harvested by vacuum filtration onto glass 
fiber filters and the radioactivity measured by liquid scintillation spec- 
trometry. Test compounds, dissolved at 10 mM in dimethylsulfoxide, 
were diluted in complete RPM1 1640 and added to the responder 
PBMC before addition of the stimulator PBMC. 
2.4. IL-2 Production 
The proliferation of an IL-2-dependent murine T cell line was used 
as a bioassay 1271 for the production of IL-2 bioactivity in the MLR 
cultures and to determine the ability of compounds to affect IL-2- 
dependent cell proliferation. To test for IL-2 bioactivity, samples of 
the MLR cultures were removed after 48 h and frozen at -80°C. 
Twenty five ~1 of the culture supernatant was diluted to 100 ~1 with 
complete RPM1 1640 that contained 2.5 x lo3 CTLL-2 cells and incu- 
bated for 24 h at 37°C. The proliferation of the CTLL-2 cells was 
determined by the incorporation of [‘H]TdR as described in the MLR 
assay. The amount of IL-2 in the samples was estimated by compart- 
son to a standard curve relating CTLL-2 proliferation to recombinant 
human IL-2 concentratron. When testing the affect of compounds on 
IL-2-dependent proliferation, dilutions of the compounds in complete 
RPM1 1640 were mixed with 1 x 10“ CTLL-2 cells and 5 U/ml recom- 
binant human IL-2 in a final volume of 100 ~1. Proliferation was 
determined by the incorporation of [‘H]TdR as described above. 
2.5. FKBP binding assay 
A competition binding assay employing a recombinant FKBP-12 
fusion protein was used to determine the affinity of compounds for 
FKBP. Human FKBP-I2 was cloned as a fusion partner with CMP- 
KDO synthetase (CKS) and purified as described by Edalji et al. [24]. 
An ascomycin conjugate of alkaline phosphatase was prepared by 
active ester coupling of an ascomycin C-22 derivative (carboxymethyl 
oxime) with alkaline phosphatase (ascomycin-AP; Abbott Laborato- 
ries, Abbott Park, IL). In the assay, FKBP-CKS fusion protem was 
dissolved at 10-35 &ml in 20 mM sodium phosphate buffer, pH 7.4, 
and adsorbed to the wells of a Immuno Plate Maxisorp (Nunc, Naper- 
ville, IL) by incubation at ambient emperature for 2 h. A solution of 
phosphate-buffered saline (PBS), pH 7.4, containing 2% bovine serum 
albumin (BSA) and 0.2% Tween 20 was added to the wells to reduce 
nonspecific binding of the ascomycin-AP. After rinsing the wells with 
0.2% Tween 20 in PBS, the test compound in the PBS/BSA/Tween 20 
buffer, or buffer alone, was added to the wells. An equal volume of 
ascomycin-AP ligand at 1 @ml in PBS/BSA/Tween 20 was added to 
the wells and incubated 2 h at ambient emperature. After rinsing with 
0.2% Tween 20 in PBS, paranitrophenyl phosphate at 1 mg/ml in 0.1 
M aminomethyl propanol was added to the wells and the temporal 
change in 405 nm absorbance recorded. 
2.6. Calcineurrn phosphatase assay 
Calcineurin activity was measured by the release of [‘*P]PO, from 
a 19 amino acid residue phosphopeptide correspondmg to the RI1 
subunit of CAMP-dependent protein kinase [28] using procedures im- 
ilar to those described by Hubbard and Klee [29]. The assay buffer 
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consisted of 50 mM Tris-HCl (pH 7.4) 0.1 M NaCl, 6 mM MgCI,, 
0.1 mM CaCl,, 0.1 mg/ml BSA, 0.5 mM dithiothreitol, and 0.2% 
Tween 20. A typical assay mixture contained 3 nM calcineurin, 30 nM 
calmodulin, 3Ot&lOOO nM FKBP-12, test compound, and 1 PM 
phosphopeptide substrate [DLDVPIPGRFDRRV[‘*P]SVAAE] in a 
final volume of 50 ~1. Compounds were tested at concentrations be- 
tween 0.1 to 10,000 nM. Prior to initiation of the phosphatase reaction 
by addition of the substrate, the assay mixtures were preincubated for 
10 min at 32°C. After addition of the phosphopeptide, the assay 
mixtures were incubated for 90 min at 32°C and stopped by the 
addition of 150 ~1 of 0.1 M potassium phosphate (pH 7) in 5% trichlo- 
roacetic acid. The stopped assay mixture was applied to a 150 ~1 
column of Dowex AG 5OW-X8 (200400 mesh) equilibrated in the Cl- 
form and the free [3ZP]P0, was recovered in the eluate after a wash with 
100 ~1 of H20. Radioactivity was measured by liquid scintillation 
spectrometry. To calculate the compound concentration which caused 
50% inhibition (IC,,) in an assay, the inhibition data was fit to a 
log-logistic linear function. 
2.7. Pharmacokinetic evaluation in the rat 
Lewis rats (obtained from Charles River, Wilmington, MA), weigh- 
ing 225-250 g, were acclimated for one week in a AAALAC approved 
facility. All animals were fasted overnight prior to dosing and through- 
out the study period but were permitted free access to water. Groups 
of animals were given ascomycin 2 or its C-18-hydroxy analogue 5 at 
a dose of 5 mg/kg. Drugs were given in a 2 ml/kg volume of 10% 
ethanol, 40% propylene glycol and 2% cremophore in 5% dextrose 
solution for both oral (p.0.) and intraperitoneal (i.p.) administration, 
and in a 1 ml/kg volume of the same vehicle without cremophor for 
intravenous (i.v.) dosing. Blood samples were collected from the tail 
vein m heparinized tubes at selected time points 0.1,0.25,0.5, 1.0,2.0, 
3.0 and 4.0 hr after dosing. 
Drugs were separated from the hemolyzed whole blood contamt- 
nants utilizing liquid-liquid extraction with ethylacetate/hexane (1:1 
by volume). Samples were centrifuged at 1200 x g for 10 min (4°C) and 
a constant volume of the organic layer was transferred to a conical 
centrifuge tube and evaporated to dryness with a gentle stream of dry 
air over low heat (- 35°C). The samples were reconstituted with 40% 
(v/v) acetonitrile in water with vortexing. The compounds of interest 
were separated from the co-extracted components by a 5 cm x 4.6 mm, 
3 pm Spherisorb ODS-2 column (Regis, Morton Grove, IL) with an 
acetonitrile/methanol/O.l% trifluoroacetic acid-O.01 M tetramethyl- 
ammonium perchlorate mixture (45:5:50 by volume for ascomycin 1, 
40:5:55 for C-18-hydroxy analogue 3) at a flow rate of 1.0 mYmin with 
UV detection at 205 nm. The temperature of the HPLC column was 
maintained at 70°C. 
The concentration of each sample was calculated by a least squares 
linear regression analysis of the peak area compared to spiked rat 
blood standards. The following pharmacokinetic parameters were de- 
termined. Maximum whole blood concentrations (C,,,,,) and the time 
of their occurrence (t,,,) were compiled from the raw data. Terminal 
half-life (tl:) was calculated from the elimination rate constant. The 
volume of distribution (V,) of i.v. drugs was estimated by standard 
techniques. Area under the blood drug concentration-time curve 
(AUC) up to the last measured blood concentration over the time 
course was also analyzed. Bioavailability was evaluated as the fraction 
derived by dividing the oral AUC by the AUC after iv. administra- 
tion. 
2.8. Popliteal lymph node (PLN) hyperplasia assay 
Inbred male rats 125-150 gwere purchased from Harlan Sprague- 
Dawley, Inc. (Indianapolis, IN) and housed for one week before use. 
Spleen cells from Brown Norway rats (RT-1”) were subjected to am- 
monium chloride to lyse red cells, washed in phosphate-buffered saline 
(PBS), X-Irradiated (2000 rads), washed again and injected subcutane- 
ously with a 27-gauge needle in the right hind foot of Lewis strain rats 
(RT-1’) using 5 x 106/100@. Test compound was dissolved in a vehicle 
consisting of 10% ethanol, 40% propylene glycol, and 2% cremophore 
with the balance being sterile 5% dextrose in water (Abbott Laborato- 
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ries, Abbott Park, IL). Two ml/kg, i.p. was given to groups of 8 
animals once daily, on days t&3. On day four, the popliteal lymph 
nodes were removed and weighed on a microbalance. The mean 
weight of nodes from a group of uninjected control animals was 
subtracted to determine the net increase, and percent inhibition in 
reference to a vehicle control group was calculated. 
2.9. Statistical analysis 
Unless indicated, all data are presented as the mean + S.E.M. and 
were analyzed using Student’s t-test of unpaired samples. 
3. RESULTS 
3.1. Synthesis of ascomycin analogues 
The C- 18-hydroxy-ascomycins were synthesized by 
two different routes, as shown in Scheme 1. A direct 
oxidation of ascomycin by selenium oxide-tert-butylhy- 
drogen peroxide in methylene chloride gave three major 
products in a ratio of 1:3:4. Each of the products was 
isolated and characterized as C-23,24-dehydro 2, C- 
23,24-dehydro-C-18-hydroxy 3, and C-l 8-hydroxy de- 
rivative 5, respectively. The C-18 hydroxyl derivative 
obtained was found to be a single isomer and the stere- 
ochemistry was assigned by NMR as the [q configura- 
tion at C-18 composition [30]. Since the C-18[R]-isomer 
was not isolated in the direct oxidation of 2, and dehy- 
dration at C-23 and C-24 was observed as a main side 
reaction, the hydroxyl groups at C-24 and C-32 were 
protected with tert-butyldimethylsilyl (TBDMS) groups 
0CH3 
0 IX-506: R= ally1 
(2) Ascomycin: R= ethyl 
Fig. 1. Structures of macrocyclic immunosuppressive agents: FK-506 
and ascomycin. 
to yield &. After the selenium oxide oxidation of&was 
performed, two products in a ratio of 1:3 were isolated 
and purified. The minor compound was identified as 
C-24,32-bis-TBDMS-C-18[R]-hydroxy-ascomycin 2 
and the major one was determined as its C- 18[&J isomer 
2b. Oxidation of the C-18 hydroxyl group to the corre- 
sponding ketone was performed by treatment with 
tetrapropylammonium perruthenateliv-methylmor- 
pholine-iv-oxide in methylene chloride. Deprotection 
with hydrogen fluoride in acetonitrile (HF-CH,CN) 
provided the C-18 ketone, 2, in moderate yield. Re- 
moval of TBDM.S groups from 2c by HF-CH,CN gave 
exclusively analogue @, whereastreatment of 2c with 
pyridiniump-toluenesulfonate in ethanol yieldedthe de- 
sired C-l 8[R]-hydroxy-ascomycin 6 in 60% yield. Acti- 
vation of the C-18 hydroxyl group of 2b with 
trifluoromethanesulfonic anhydride or methanesulfonyl 
chloride instantly yielded compound 9 The C-18 acyl- 
ated analogues 10-12 were obtained from the deprotec- 
tion of the corresponding bis-TBDMS analogues by 
HF-CH,CN, respectively. Under these conditions, com- 
pound 8 was also isolated in each case, and the ratio of 
the de&ed acylated analogues versus 8 were 1:l S for 
0, 3.5:l for lJ, and 1: 1 for lJ, respectively. All com- 
pound gave satisfactory analytical data, and detailed 
synthetic procedures will be published elsewhere. 
3.2. Inhibition of lymphocyte proliferation (MLR) 
As an in vitro model of allogenic T lymphocyte acti- 
vation, human peripheral blood mononuclear leukocyte 
(PBL) are exposed to a pool of mitomycin C-treated 
PBL. After four days, the incorporation of [3H]thymid- 
ine into cellular DNA is measured. FK-506 1, ascomy- 
tin 2 and rapamycin 2 showed complete inhibition of 
this response with ICsO values of subnanomolar to pico- 
molar (Table I). In contrast, C-18-[Sl and [Rl-hydroxy- 
ascomycin analogues 5 and 6 as well as analogues 7-11 -- 
did not show any sigmficant inhibitory activity, except 
compound lJ, which displayed a very weak inhibition 
(MLR = 0.17 PM). 
3.3. FKBP binding activity 
The discovery of cis-trans peptidylprolyl isomerase 
(PPIase or rotamase) activity for this cytoplasmic 
FKBP raised some very interesting questions whether 
this activity mediates the immunosuppressive action of 
FK-506. But. as has been pointed out earlier, the inhibi- 
tion of PPIase activity of FKBP is not sufficient to 
mediate the immunosuppressive activity [18]. However, 
because FKBP binding appears to be necessary for im- 
munosuppressive activity, we investigated the ability of 
synthetic analogues to bind. Data from a binding assay 
using cloned FKBP fused to CMP-KDO synthetase 
(CKS) as a receptor (Table I), showed that natural li- 
gands 1,2, and 3 as well as analogues 5 and 6 compete 
with an average IC,, of 0.9, 1.4, 2.9, 4.6 and 1.8 nM, 
respectively. Compounds 2, 9 and 11 were shown to _ - 
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(2a, R1=TF3DMS,Rz=R3=H W 
(28, R1=TBDMS,R2=OH, R3=H[Sj 
(&) R1 = TBDMS, R2 = H, R3 = OH [RI 
% J=$;~_~~~o_; + @) 
& 
(111, R = Methyl 
(l& R=Phenyl 
(12, R = Iodomethyl 
Reagents 
(i) Se02-THBP, (ii) TBDMS-Cl, DMAP, DMF, (iii) TPAP-NMMO, CH@2, (iv) HF-AcCN 
(v) Pyridinium p-Toluenesulfonate, (vi) (TfO)20, (vii) Acyl anhydride or Acyl halide 
Scheme 1. Synthetic routes of Ascoumycin analogues 
possess weaker activities with I&, values of 17, 25 and 
41 nM, respectively. The data clearly suggest hat, with 
the exception of s, all of the synthetic analogues bind 
tightly to FKBP. 
3.4. Inhibition of IL-2 production and CTLL-cell line 
Potent inhibition of IL-2 production (cyclosporin A 
and FK-506) and inhibition of cellular responses to IL-2 
(rapamycin) appear to be critical, but perhaps diver- 
gent, mechanisms by which these immunosuppressants 
inhibit T lymphocyte proliferation [31]. Thus, inhibition 
of IL-2 production and inhibition of IL-2 induced pro- 
liferation of CTLL-2 cells was studied. Most of the 
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synthetic analogues 511 caused no inhibition in either -- 
IL-2 or CTLL assays, as were expected based on their 
lack of activity in the MLR assay and in contrast to 
immunosuppressants 14 which inhibit these events -- 
(Table I). One exception is analogue 12, which exhibited 
weak but detectable inhibition in the MLR, IL-2 and 
CTLL assays. 
3.5. Evaluation of antagonism 
Because the C18-[SJ-hydroxy analogue 5 retained a 
high binding affinity for FKBP-12 but did not have 
demonstrable immunosuppressive activity, it was evalu- 
ated for its ability to reverse the inhibitory effects of 
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Table I 
In vitro biological data for synthetic analogues of ascomycin 2 
Modifications” MLR 
(nMS’ 
FKBP 
@MI 
CTLL 
(&d (nM) 
(1) 
(2) 
(3) 
(4) 
(51 
(6) 
(7) 
(8) 
(91 
(101 
(111 
(121 
FK506 
Ascomycin 
Rapamycin 
CsA 
Cl 8-[#OH 
Cl 8-[RI-OH 
Cl 8-Keto 
C 18-ene-CZO-oxa 
Cl5deMe- Cl5,18oxa 
C18-[q-O-AC 
Cl8-[q-OBzo 
Cl 8-[Sj-0-IAc 
0.03 0.9 
0.08 1.4 
0.32 2.9 
4.8 7% @ 10,uM 
na.’ 4.6 
n.a. 1.8 
n.a. 17.0 
n.a. na. 
n.a. 25 
n.a. 3.2 
n.a. 41 
170 1.3 
a See Scheme 1 for structures. 
b Inhibition of allogeneic T lymphocyte proliferation. 
’ The binding activity of compound to FKBP. 
d Inhibition of IL-2 production by allogeneic stimulated T lymphocytes. 
e Inhibition of IL-2 induced proliferation of CTLL-2 cells. 
‘Not active at 0.1 PM inhibitor concentration. 
* Activity at 0.1 ,uM inhibitor concentration. 
FK-506 in the MLR and the calcineurin phosphatase 
assay. In data not shown, analogue 5 caused no inhibi- 
tion of calcineurin phosphatase activity at concentra- 
tions up to 10 PM. As shown in Fig. 2, analogue 2 at 
a concentration IOOO-fold higher than the FK-506 
caused a significant reversal of FK-506’s inhibition in 
the mixed leukocyte response assay. A ten-fold lower 
concentration of the analogue 5 was ineffective. Simi- 
larly, the inhibition of calcineu& phosphatase caused 
by a 10 nM concentration of FK506 l was significantly 
reversed by 1 and 10 ,uM concentration of 5, as shown 
in Fig. 3. 
3.6. Pharmacokinetic studies 
Values of primary pharmacokinetic parameters in 
rats after a single dose of drugs with various administra- 
0 
Unstlmtdsted Stimtdatad 1 IlY (1) +o.l)rM(s) l 1.OfiY(5) 
Fig. 2. Reversal by compound 1 of the inhibition by compound 1 of 
cell proliferation in the MLR. *P < 0.001, when compared to the 
control stimulated response. 
0.001 370 
0.001 350 
_ 0.06 
_ 
n.a. 
n.a. 
na. 
na. 
n.a. 
n.a. 
n.a, 
270 
8%* 
_ 
11% 
n.a. 
_ 
_ 
- 
31 
tion routes are shown in Table II. Analogue 2 was found 
to have a shorter iv. half-life than ascomycin 2, al- 
though its volume of distribution was comparable. 
After oral gavage, the peak blood level and AUC for 2 
were two to threefold higher than with analogue 5, and 
no trace of the latter could be seen after four hours. 
Bioavailability comparable to ascomycin 2 has been 
reported for FK-506 in human [32] and rat [33,34] after 
oral dosing. In contrast to its low oral availability, ana- 
logue 5 was comparable in peak concentration and 
AUC to ascomycin 2 when given i.p. and had a better 
bioavailability. 
3.7. In vivo PLN assay 
The popliteal lymph node (PLN) hyperplasia re- 
sponse to alloimmune challenge with histoincompatible 
g + e s 
+ 
P 
E 
? 
z P 
F 
0 
r 
Fig. 3. Reversal by compound 5 of compound 1 inhibition of cal- 
cineurin phosphatase. *P < 0.02, when compared to the 10 nM l 
sample. 
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Table II 
Pharmacokmetic parameters of ascomycin 2 and Cl8OH analogue 
5 in rats after single intravenous (i.v.), oral (p.o.), or intraperitoneal 
(i.p.) administration at a dosage of 5 mg/kg body weight 
i.v. 
Compound 
(?) (5) 
p.0. i.p. i.v. p.0. i.p. 
_ 0.5 0.5 t,,, (h) 0.25 0.25 
_ 390 519 C,,, (@ml) I 182 636 
2.05 ~ _ tl/> (h) 1.29 - _ 
2.07 - _ V, Wkg) 2.28 - _ 
2984 778 1878 AUC (ng.hr/ml) 1210 200 1650 
_ 26 62 Bioavailability (%) - 16 137 
splenocytes injected in the foot, was used as an in vivo 
model of lymphoproliferation. As shown in Fig. 4, the 
average control response to splenocyte injection (stimu- 
lated) was twofold higher than with buffer alone (un- 
stimulated). With administration of 5 at a dose of 30 
mg/kg/day, i.p., the average challenged node weight was 
not significantly different from the vehicle control. In 
contrast, ascomycin 2 was found to have an ED,, of 0.3 
mg/kg/day, i.p., for inhibiting the node weight increase. 
4. DISCUSSION 
An earlier report identified protein phosphatase cal- 
cineurin as a common target for FKBP-FK506 and 
cyclophilin-CsA complexes [121. These complexes, not 
immunosuppressant alone nor immunophilin alone, in- 
hibit calcineurin phosphatase activity. The inhibition of 
this phosphatase activity may be an early step in a series 
of events that results in the inhibition of T cell cytokine 
gene transcription [19]. In this study, the biological as- 
pects of the interactions between synthetic ligands and 
FKBP, and ligand/FKBP complexes and calcineurin 
were investigated. Data, summarized in Table I, show 
that various reference immunosuppressants 14 po- 
tently inhibit allogeneic T lymphocyte proliferation. In 
contrast, C-1%hydroxy analogues 2 and 5 as well as 
analogues 7-11 did not inhibit the human mixed lym- -- 
phocyte reactions nor inhibit IL-2 production by allo- 
geneically stimulated T lymphocytes. In fact, one of the 
C-l 8 hydroxyl analogues with unspecified stereochem- 
istry has been reported to antagonize both FK-506 and 
rapamycin, but not cyclosporin A, inhibition of T-cell 
response to PMA or IL-2 plus PMA [22]. These obser- 
vations raise many questions with respect to immuno- 
suppressive activity. (1) Do the non-immunosuppres- 
sive analogues bind tightly to FKBP, similar to 1 and 
2? (2) If so, are the FKBP-bound conformations of 
analogues 5 and 6 different from those of 1 or z? (3) Are 
observed binding affinities to FKBP comparable to 
those of 1 and 2? (4) Are the complexes of FK-506 
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analogue/immunophilin capable of inhibiting cal- 
cineurin? (5) Can they antagonize the effects of FK-506? 
(6) Do the in vitro data predict in vivo properties? 
First, we investigated the binding activity of com- 
pounds to FKBP (Table I). Although the functional role 
of the major intracellular binding protein, FKBP-12, 
remains poorly understood, one approach to address 
this issue is to study the relationship between immuno- 
suppression and FKBP binding activity of a series of 
structurally related analogues. The significant similarity 
in structure resulted in similar FKBP binding affinity 
among A,& 5 and 6. Other analogues, such as I,?, and 
11 have comparatively weak binding affinities. 
We felt an understanding of the secondary and terti- 
ary structure of FKBP/analogue complexes might be 
helpful in rationalizing their biological effects. We 
therefore determined the three-dimensional structure of 
two analogues 5 and 6, when bound to [U- 
‘3C,‘5N]FKBP by isotope-filtered 2D NMR experi- 
ments [30]. From a comparison of the 3D structure of 
the analogues 5, 5 with ascomycin 2 when bound to 
FKBP, it was concluded that the bound conformations 
of 3 and 6 are virtually identical to the bound conforma- 
tion of 2 [30]. Thus, substitution of a hydroxyl group at 
the C-18 position has essentially no effect on the confor- 
mation of the bound ligands, and the lack of immuno- 
suppressive activity, therefore cannot be explained by 
altered bound conformation. 
When tested in the rat PLN assay, an in vivo model 
of lymphoproliferation, analogue 5 was devoid of im- 
munosuppressive activity (Fig. 4) despite its good bi- 
oavailability relative to 2 and having been given at a 
dose (30 mg/kg/day) much higher than that required for 
immunosuppression with 2. This observation is consis- 
tent with the lack of in vitro inhibitory activity dis- 
played by compound 5. The lack of immunosuppressive 
activity of 5 in vitro and in vivo led us to investigate the 
interaction of FKBP complex with calcineurin. The im- 
munophilin complexes with either 5 or 5 do not inhibit 
calcineurin, whereas the complexes with 1 or 2 inhibit 
“2 
Fig. 4. Effect of compounds of 5 and 2 on popliteal lymph node 
hyperplasia in the rat. *P < 0.05 when compared to the control stimu- 
lated response. 
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calcineurin phosphatase activity with I&, values of 4 
and 10 nM, respectively. To date, there is no direct 
evidence that the immunophilin complexes with 5 or 6 
do not bind calcineurin, but as has been pointed out 
earlier [30] introduction of a C-18 hydroxyl group to a 
hydrophobic, calcineurin binding site could disrupt the 
hydrophobic surface and inhibit binding of calcineurin 
to the complex. Because analogue 5 did not have de- 
monstrable immunosuppressive activity, but showed a 
high affinity for FKBP-12, investigation of its ability to 
reverse inhibition of calcineurin caused by FK-506 is 
also very important to confirm the central role of cal- 
cineurin in the immunosuppressive action. As shown in 
Fig. 2, analogue 3 at a concentration IOOO-fold higher 
than FK-506 caused a significant reversal of FK-506’s 
inhibition in the mixed leukocyte response assay. Ana- 
logue 5 also blocked the inhibition of calcineurin phos- 
phatase caused by FK-506 (Fig. 3), suggesting that 
these two compounds could bind to a common binding 
region of FKBP and interact with calcineurin in a com- 
petitive fashion. 
5. CONCLUSION 
In this investigation, we have systematically studied 
the biological and physiological activities of several non- 
immunosuppressive analogues of FK-506. Despite the 
fact that FK-506 analogues such as 5 and 4, bind to 
FKBP-12 with virtually identical affinity and bound 
conformation relative to 1 and 2, these compounds lack 
immunosuppressive activity both in vitro and in vivo. 
Competitive antagonism of FK-506 effects using 5 was 
demonstrated in MLR and calcineurin assays. The PLN 
assay results show that analogue 5 was devoid of in vivo 
immunosuppressive activity despite its comparable bi- 
oavailability relative to 2. Although no direct evidence 
has not yet been obtained regarding the ability of the 
immunophilin complexes with 5 or 6 to bind cal- 
cineurin, we suggest hat the C-l 8 hydroxy group could 
disrupt the hydrophobic surface and inhibit binding of 
calcineurin to the complex. 
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